Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
12h
Strong Q3 Performance and Future Growth Prospects Justify Buy Rating on Sarepta Therapeutics
William Blair analyst Sami Corwin has maintained their bullish stance on SRPT stock, giving a Buy rating today. Sami Corwin’s rating is ...
22h
Vaxcyte’s Strong Market Position and Financial Health Justify Buy Rating with $153 Target
Leerink Partners analyst David Risinger reiterated a Buy rating on Vaxcyte (PCVX – Research Report) on November 5 and set a price target ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
3 charged in Payne's death
Biden addresses nation
Fed cuts interest rates
Immigration policy blocked
Trump picks chief of staff
Germany arrests US citizen
Proposes decongestant ban
Wins in Pennsylvania
Fired by Philadelphia Union
Newsom calls special session
Jury deliberations begin
Jackson mayor indicted
9/11 plea deals revived
43 monkeys escape SC lab
NYC hotel fraud ruling
Ellison begins 2-yr sentence
New Pompeii DNA evidence
AU plans social media ban
Snow back on Mount Fuji
Flips PA Senate seat
Wholesale inventories fall
Facebook shareholder suit
Giuliani appears in court
Volcano erupts in Indonesia
Time to get flu, COVID shots
Pledges 'orderly' transition
Expands bird flu testing
Mortgage rates rise again
Weekly jobless claims rise
Feedback